# NCT05318469 (NCT05318469)

> Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05318469
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Yuan Yuan
- Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; HR+ / HER2- Advanced Breast Cancer
- Interventions: Ivermectin; Balstilmab; Pembrolizumab
- Enrollment: 34
- Primary outcome: Incidence of adverse events
- Primary outcome: Objective response rate

## Indexed commentary on NCT05318469 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05318469
